ALEXANDRIA, Va., March 19 -- United States Patent no. 12,252,524, issued on March 18, was assigned to Eli Lilly and Co. (Indianapolis).
"GIP/GLP1 co-agonist compounds" was invented by Jorge Alsina-Fernandez (Indianapolis), Robert Andrew Brown (Carmel, Ind.), Mohamed ElSayed Hamed ElSayed (Fishers, Ind.), Hongchang Qu (Carmel, Ind.), Huyen Thanh Tran (Bargersville, Ind.), Aktham Aburub (Carmel, Ind.) and Phenil Jayantilal Patel (Carmel, Ind.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds ha...